Tuesday, August 6, 2019 @ 12:00 am
InterAx Biotech AG announced today that it has entered an agreement with Boehringer Ingelheim to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.
InterAx and Boehringer will collaborate to characterize drug candidates for an undisclosed target. “We are looking forward to combining our unique technology with the expertise of Boehringer Ingelheim to identify compounds with superior biological properties for one of Boehringer’s target receptors”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.